<DOC>
	<DOCNO>NCT02170792</DOCNO>
	<brief_summary>To assess extent absorption 12.5 , 50 200 mg BIBR 1048 MS without coadministration 150 mg ranitidine .</brief_summary>
	<brief_title>Bioavailability BIBR 953 ZW After Dose BIBR 1048 MS</brief_title>
	<detailed_description />
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>healthy male subject determine result screen sign write informed consent accordance GCP local legislation age &gt; = 18 &lt; = 50 year Broca &gt; = 20 % &lt; 0 + 20 % find medical examination ( include blood pressure , pulse rate ECG ) history current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder history orthostatic hypotension , faint spell blackouts disease central nervous system ( epilepsy ) psychiatric disorder chronic relevant acute infection History : allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator bleed disorder include prolonged habitual bleeding hematologic disease cerebral bleeding ( e.g . car accident ) commotio cerebri intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration use drug might influence result trial within 10 day prior administration administration participation another trial investigational drug within 2 month prior administration trial smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day alcohol abuse ( &gt; 60 g / day ) drug abuse blood donation within 1 month prior administration trial excessive physical activity within 5 day prior administration trial laboratory value outside clinically accept reference range history familial bleeding disorder Thrombocytes &lt; 150000 /Âµl</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>